By: Jonathan Gardner
An alliance with Rona Therapeutics adds to a particularly active stretch for Roche and makes the company the latest to bet on medicines that can lower levels of “visceral” fat.
Jonathan Gardner is a Senior Reporter at BioPharma Dive. He focuses on themes related to medicine and healthcare, including pharmaceuticals, medical technology, and alternative medicine, with particular attention to topics such as pharmaceutical manufacturing, regulation, oncology, and immunotherapy. Jonathan's work has been featured in prominent outlets including Healthcare Dive, Yahoo Finance, and PharmaVoice.
